Radioimmunotherapy

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Retrieved on: 
Monday, March 4, 2024

to the Company’s Board of Directors, effective February 29, 2024.

Key Points: 
  • to the Company’s Board of Directors, effective February 29, 2024.
  • Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors.
  • “We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs,” said Michael Rossi, President and Chief Executive Officer.
  • Nektar is a clinical-stage, research-based drug discovery biopharmaceutical company focuses on discovering and developing innovative medicines in the field of immunotherapy.

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 5:15pm PT.

Key Points: 
  • NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 5:15pm PT.
  • A live webcast of the presentation and any accompanying presentation materials will be available under the Events section of the Company’s Investor Relations website at www.ymabs.com.
  • The webcast will be archived for at least 30 days.

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, November 13, 2023

During the third quarter ended September 30, 2023, approximately 63% of the vials sold in the U.S. were sold outside of Memorial Sloan Kettering Cancer Center (“MSK”), compared to 61% in the second quarter ended June 30, 2023.

Key Points: 
  • During the third quarter ended September 30, 2023, approximately 63% of the vials sold in the U.S. were sold outside of Memorial Sloan Kettering Cancer Center (“MSK”), compared to 61% in the second quarter ended June 30, 2023.
  • Cost of goods sold was $2.6 million and $2.5 million for the third quarter ended September 30, 2023 and 2022, respectively.
  • Research and development expenses were $15.4 million for the third quarter ended September 30, 2023, a reduction of 32% compared to $22.5 million for the third quarter ended September 30, 2022.
  • Selling, general, and administrative expenses were $10.2 million for the third quarter ended September 30, 2023, a reduction of 25% compared to $13.6 million for the third quarter ended September 30, 2022.

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

Retrieved on: 
Wednesday, October 18, 2023

“Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.

Key Points: 
  • “Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.
  • “We are extremely grateful for Thomas’s successful leadership and dedication as Interim CEO.
  • We look forward to Thomas’s continued leadership in his new role as Vice Chairman of the Board of Directors and Chief Business Officer of Y-mAbs.”
    Mr. Rossi said, “I have long admired Y-mAbs as a leader in the development of transformative cancer therapies.
  • Y-mAbs is a pioneer in pretargeted radioimmunotherapy with its SADA Technology and diverse pipeline of promising SADA programs, and a science-driven, patient-first culture.

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

Retrieved on: 
Tuesday, October 17, 2023

The primary study outcome will evaluate safety and initial signals of efficacy using repeated dosing.

Key Points: 
  • The primary study outcome will evaluate safety and initial signals of efficacy using repeated dosing.
  • Y-mAbs expects a total of approximately 30 patients and up to 12 U.S. sites to be included in the trial.
  • The SADA technology platform utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target.
  • Unbound constructs predictably disassemble into smaller antibody fragments and are predominantly excreted through the kidneys within hours after administration.

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

Retrieved on: 
Friday, May 26, 2023

Dose escalation is based two patients in cohort 1 and 2, followed by a classical 3+3 design.

Key Points: 
  • Dose escalation is based two patients in cohort 1 and 2, followed by a classical 3+3 design.
  • The study is actively enrolling, and the Company expects Parts A, B, and C will include 18, 12, and 32 patients, respectively, across 6-10 U.S. sites.
  • In a second infusion, a radioactive payload designed specifically to target the SADA molecules attached to the tumor target.
  • Researchers at MSK developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs.

PharmAbcine to participate in "BIO International Convention 2023"

Retrieved on: 
Monday, May 8, 2023

DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023.

Key Points: 
  • DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023.
  • Details of the events are as follows:
    PharmAbcine will participate in BIO International Convention to introduce the Company's core technology and pipeline assets to discuss potential out-licensing and co-development opportunities with global pharmaceutical and biotech companies.
  • Olinvacimab, an anti-VEGFR2 antibody, is currently undergoing phase II clinical trial for metastatic triple-negative breast cancer (mTNBC) patients.
  • The study combines olinvacimab with Keytruda® (pembrolizumab), an anti-PD-1 antibody developed by Merck Sharp & Dohme Corp (MSD).

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

Retrieved on: 
Wednesday, April 5, 2023

“We are excited to advance our SADA platform into the clinic for the first time with the initiation of patient dosing in this trial.

Key Points: 
  • “We are excited to advance our SADA platform into the clinic for the first time with the initiation of patient dosing in this trial.
  • This is a significant milestone for Y-mAbs in our efforts to potentially build a global franchise of radiotherapeutic assets,” said Thomas Gad, Founder, President, and Interim CEO.
  • “SADA can potentially generate the clinical data to further unlock the potential of radiolabeled therapeutics in tumors that have not historically demonstrated meaningful responses.
  • The Company expects a total of approximately 60 patients to be enrolled in the trial across 6-10 U.S. sites.

Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics

Retrieved on: 
Friday, November 25, 2022

OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").

Key Points: 
  • OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").
  • Malene Brondberg, Interim CEO and CFO of Nordic Nanovector, says: "We are happy that so many shareholders attended the webcast we hosted yesterday, where we provided more background on the proposed merger with APIM Therapeutics.
  • After a week of highly productive meetings between the Nordic Nanovector and APIM teams, our confidence in a merged company is even stronger than before.
  • This review included carefully evaluating a potential stand-alone strategy for Nordic Nanovector, which was deemed not to be a viable option by the Board.

Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics

Retrieved on: 
Friday, November 25, 2022

OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").

Key Points: 
  • OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").
  • Malene Brondberg, Interim CEO and CFO of Nordic Nanovector, says: "We are happy that so many shareholders attended the webcast we hosted yesterday, where we provided more background on the proposed merger with APIM Therapeutics.
  • After a week of highly productive meetings between the Nordic Nanovector and APIM teams, our confidence in a merged company is even stronger than before.
  • This review included carefully evaluating a potential stand-alone strategy for Nordic Nanovector, which was deemed not to be a viable option by the Board.